Trials / Completed
CompletedNCT00636545
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of Genasense Administered as a 2-hour Intravenous Infusion to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Genta Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oblimersen (Genasense) | Intravenous |
| DRUG | Oblimersen (Genasense) | Intravenous |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-03-01
- Completion
- 2010-03-01
- First posted
- 2008-03-14
- Last updated
- 2012-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00636545. Inclusion in this directory is not an endorsement.